Memantine - Wikipedia, the free encyclopedia
Memantine is also being tested for opioid dependence, systemic lupus ... adverse effects include: vomiting, anxiety, hypertonia, cystitis, and increased ...
Namenda (Memantine), Alzheimer's medication
Namenda (Memantine)is a medication used in the treatment of Alzheimer's. ... Anxiety Disorders. Bipolar. Depression. Dissociative Disorders. Eating Disorders ...
A 10 Week Open-Label Pilot Study to Evaluate the Effectiveness and ...
... Memantine(Namenda) as Augmentation Therapy in Patients With Generalized Anxiety Disorder ... General Anxiety Disorder, Social Anxiety Disorder. Drug: ...
Memantine:The Newest Alzheimer's Medication
Memantine ... Memantine was approved by the FDA in October as the newest treatment option for ... Ads By Google. All Natural Choice for Anxiety ...
Namenda Study for Anxiety
You will begin memantine treatment in addition to your primary SSRI or SNRI medication. You will take 5mg per day of memantine. ...
Memantine - Yahoo! Health
Before using memantine, tell your doctor if you are allergic to any drugs, or if ... anxiety, aggression; skin rash; redness or swelling of or around your eyes; or ...
memantine.com - The role of neurochemical mechanisms of ventromedial ...
... serotonin, and sulpiride in the ventromedial hypothalamus reduced anxiety in an ... Memantine is now available in the USA. For more information, please ...
Drug Information for Memantine Oral - WebMD
Find medical information for Memantine Oral including side effects, drug interactions, images ... Anxiety Symptom Control. Atherosclerosis? Baby Care Central ...
Images of Memantine Oral - WebMD
View pictures of Memantine Oral including drug dosages and medical information and advice on ... Anxiety Symptom Control. Atherosclerosis? Baby Care Central ...
MEMANTINE - ORAL (Namenda) side effects, medical uses, and drug ...
Read more about the prescription drug MEMANTINE - ORAL. ... changes (e.g., depression, agitation, anxiety), swelling of hands or feet, trouble breathing. ...
|
Forest Laboratories, Inc. Announces Positive Results of Memantine Study of Once-Daily...
| Reuters
Forest Laboratories, Inc. Announces Positive Results of Memantine Study of
Once-Daily Formulation
NEW YORK, Feb. 5 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc.
(NYSE: FRX) today announced preliminary results of a Phase III study of
memantine HCl (currently marketed as Namenda(R), a twice-daily immediate-
release formulation) in a novel once-daily formulation. The study evaluated
the efficacy, safety, and tolerability of an innovative, proprietary, 28 mg
memantine extended-release, once-daily formulation compared to placebo in
outpatients with moderate to severe Alzheimer's disease currently treated with
a cholinesterase inhibitor. The results indicate that patients treated with
memantine 28 mg extended-release formulation experienced statistically
significant benefits in cognition and clinical global status compared to
placebo.